Menu

Superimposed over a collection of lifestyle pictures of couples and single people is a heading that says:

All individuals and models used in this website are for illustrative purposes only. They have given consent for use of their images and received remuneration from ViiV Healthcare.

Indication: APRETUDE is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg.[1]

START A NEW CHAPTER IN HIV-1 PREVENTION WITH APRETUDE

Creating a new narrative for people who could benefit from PrEP with APRETUDE[2]

APRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with safer sex practices for PrEP to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg.[1]

APRETUDE is the first and only long-acting injectable PrEP medication[2,3]

Superior efficacy vs daily oral TDF/FTC[2]

Significant reduction in the risk of HIV-1 acquisition vs daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in cisgender men and transgender women who have sex with men (p=0.0003)[4] and in cisgender women (p<0.0001).[5]

Find out more

Preferred choice of PrEP over TDF/FTC in clinical trials

Most US participants entering the open-label extension (OLE) of HIV Prevention Trial Network (HPTN) 083 and HPTN 084 chose APRETUDE over daily oral TDF/FTC as their preferred pre-exposure prophylaxis (PrEP) option to complete the study.

Find out more

Adherence you can confirm[2]

With 1 injection every 2 months, after initiation, administered by a healthcare professional.[2]

Find out more

Studied in a broad trial population[2,4,5]

APRETUDE is supported by a broad body of evidence from two diverse and comprehensive HIV-1 prevention trials, including cisgender men and transgender women who have sex with men, and in cisgender women.[2,4,5]

Find out more

Find out who is suitable for long-acting HIV-1 prevention with APRETUDE in your practice

Explore our safety data

Access downloadable versions of the risk minimisation materials
Montage of lifestyle pictures of couples.

HIV-1, human immunodeficiency virus type 1; HPTN, HIV Prevention Trials Network; INSTI, integrase strand transfer inhibitor; OLE, open-label extension; PrEP, pre-exposure prophylaxis; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine.

References:

  1. APRETUDE (cabotegravir) Summary of Product Characteristics.
  2. Delany-Moretlwe S et al. Presented at IAS 2023. 23-26 July. Brisbane, Australia. 5998.
  3. https://www.medicines.org.uk/emc/product/15696/smpc, Accessed August 2024
  4. Landovitz RJ et al. N Engl J Med. 2021;385(7):595–608.
  5. Delany-Moretlwe S et al. Lancet. 2022;399(10337):1779–1789.
  6. Clement ME et al. Presentation at the 30th Conference on Retroviruses and Opportunistic Infections (CROI). 19–22 February 2023. Seattle, Washington, USA. 994.

PM-GB-CBT-WCNT-240002 October 2024

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.